FAQ

PNU 166196

Known as: PNU-166196, PNU166196 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2000-2009
01220002009

Related topics

Related topics

1 relation

Broader (1)

brostallicin

Related mentions per year

Related mentions per year

2000-2014
20002005201020152020
PNU 166196
brostallicin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity.
Brostallicin (PNU-166196), a-bromo-acrylamido tetra-pyrrole derivative, showed high cytotoxic potency and myelotoxicity… (More)
Is this relevant?
2004
2004
Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
The mechanism of action of many antitumor agents involves DNA damage, either by direct binding of the drug to DNA or to DNA… (More)
Is this relevant?
2003
2003
Brostallicin (PNU-166196) – a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells
Defects in DNA mismatch repair (MMR) are associated with a predisposition to tumorigenesis and with drug resistance owing to high… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2003
2003
Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.
PURPOSE Brostallicin (PNU-166196) is a cytotoxic agent that binds to the minor groove of DNA with significant antitumor activity… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2003
2003
Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.
PURPOSE Brostallicin (PNU-166196) is a alpha-bromoacrylic DNA minor groove binder, currently in clinical evaluation. This drug… (More)
Is this relevant?
Review
2003
Review
2003
The discovery of a new potential anticancer drug: a case history.
DNA minor groove binders (MGB) represent a class of anticancer agents whose DNA sequence specificity was hypothesized to lead to… (More)
Is this relevant?
2002
2002
Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
Brostallicin (PNU-166196) is a synthetic alpha-bromoacrylic, second-generation DNA minor groove binder structurally related to… (More)
  • figure 1
  • table 1
  • table 2
  • table 4
  • figure 2
Is this relevant?
2001
2001
A new class of cytotoxic DNA minor groove binders: alpha-halogenoacrylic derivatives of pyrrolecarbamoyl oligomers.
DNA minor groove binders represent a class of cytotoxic antitumor agents whose DNA sequence specificity may lead to a high… (More)
Is this relevant?
Review
2001
Review
2001
Development of distamycin-related DNA binding anticancer drugs.
The relatively low therapeutic index of the clinically used alkylating agents is probably related to the fact that these… (More)
Is this relevant?
2000
2000
Cytotoxic alpha-bromoacrylic derivatives of distamycin analogues modified at the amidino moiety.
The design, synthesis, in vitro and in vivo activities of novel alpha-bromoacrylic derivatives of distamycin A, modified at the… (More)
Is this relevant?